Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989495 | 0.94 | SMN1; SMN2 (0.44) | MAPTGAASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL19989259 | 0.89 | MAPT (0.43) | MAPTGAASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL19989256 | 0.88 | PIK3CA (0.41) | MAPTGAASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL19988906 | 0.88 | PIK3R2 (0.42) | MAPTGAASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL19989217 | 0.87 | MAPT (0.51) | MAPTGAASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL19988989 | 0.87 | PIK3R2 (0.41) | MAPTSMN1; SMN2PIK3R2 | |
| SCHEMBL19991582 | 0.84 | MAPT (0.44) | MAPTGAAMAPK1TDP1L3MBTL1 | |
| SCHEMBL19989026 | 0.84 | MAPT (0.40) | MAPTSMN1; SMN2MAPK1PIK3R2TP53 | |
| SCHEMBL19989021 | 0.84 | MAPT (0.49) | MAPTGAASMN1; SMN2MAPK1TDP1 | |
| SCHEMBL19991580 | 0.81 | MAPT (0.43) | MAPTGAASMN1; SMN2MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057808-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | MAPT 146/4885GAA 2943/4885SMN1; SMN2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.